TY - JOUR
T1 - The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization
AU - Zou, Jing
AU - Xie, Xuping
AU - Fontes-Garfias, Camila
AU - Swanson, Kena A.
AU - Kanevsky, Isis
AU - Tompkins, Kristin
AU - Cutler, Mark
AU - Cooper, David
AU - Dormitzer, Philip R.
AU - Shi, Pei Yong
N1 - Funding Information:
We thank colleagues at Pfizer, BioNTech, and UTMB for helpful discussions and support during the study. We thank the Pfizer-BioNTech clinical trial C4591001 participants, from whom the post-immunization human sera were obtained, and the staff of the New Iberia Research Center, who provided the rhesus macaque post-immunization sera. We thank the many colleagues at Pfizer and BioNTech who developed and produced the BNT162b2 vaccine candidate. P.-Y.S. was supported by NIH grants AI134907 and UL1TR001439, and awards from the Sealy & Smith Foundation, Kleberg Foundation, the John S. Dunn Foundation, the Amon G. Carter Foundation, the Gilson Longenbaugh Foundation, and the Summerfield Robert Foundation.
Publisher Copyright:
© 2021, The Author(s).
PY - 2021/12
Y1 - 2021/12
N2 - Initial COVID-19 vaccine candidates were based on the original sequence of SARS-CoV-2. However, the virus has since accumulated mutations, among which the spike D614G is dominant in circulating virus, raising questions about potential virus escape from vaccine-elicited immunity. Here, we report that the D614G mutation modestly reduced (1.7–2.4-fold) SARS-CoV-2 neutralization by BNT162b2 vaccine-elicited mouse, rhesus, and human sera, concurring with the 95% vaccine efficacy observed in clinical trial.
AB - Initial COVID-19 vaccine candidates were based on the original sequence of SARS-CoV-2. However, the virus has since accumulated mutations, among which the spike D614G is dominant in circulating virus, raising questions about potential virus escape from vaccine-elicited immunity. Here, we report that the D614G mutation modestly reduced (1.7–2.4-fold) SARS-CoV-2 neutralization by BNT162b2 vaccine-elicited mouse, rhesus, and human sera, concurring with the 95% vaccine efficacy observed in clinical trial.
UR - http://www.scopus.com/inward/record.url?scp=85103430539&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103430539&partnerID=8YFLogxK
U2 - 10.1038/s41541-021-00313-8
DO - 10.1038/s41541-021-00313-8
M3 - Article
AN - SCOPUS:85103430539
SN - 2059-0105
VL - 6
JO - npj Vaccines
JF - npj Vaccines
IS - 1
M1 - 44
ER -